|
|||||
|
|
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations |
|
| Authors: | Dawei Chen Xuesong Huang Jie Cai Sheng Guo Wubin Qian Jean-Pierre Wery Qi-Xiang Li |
| Affiliation: | 1. Crown Bioscience, Inc., 3375 Scott Blvd, Santa Clara, CA 95054, USA;2. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China |
| Abstract: | |
| Keywords: | biomarker PDX KRAS erbitux patient stratification |